pipette
ESEspañol

A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology

Wagner Scheeren Brum, Shorena Janelidze, Alpana Singh, Nesrine Rahmouni, Seyyed Ali Hosseini, Marisa N. Denkinger, Gleb Bezgin, Tevy Chan, Arthur C. Macedo, Joseph Therriault, Lydia Trudel, Serge Gauthier, Paolo Vitali, Geidy E. Serrano, Thomas G. Beach, Alireza Atri, Tainá M. Marques, Taraneh E Atri, Erik Stomrud, Eric M. Reiman, Jessica B. Langbaum, Peter Harrison, Claire Brooks, Michael Turton, Jon Springett, Henrik Zetterberg, Suzanne E. Schindler, Antoine Leuzy, Kanta Horie, Randall John Bateman, Craig E.L. Stark, Joshua D. Grill, Oskar Hansson, Sebastian Palmqvist, Kevin Wood, Edwin S. Monuki, William H. Yong, Elizabeth Head, Pedro Rosa-Neto, Niklas Mattsson, Nicholas J. Ashton

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Conclusions and Relevance A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.

Appeared: Wednesday, November 18. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.25143